Key Takeaways:
Incyte Corp. is closing in on a deal to acquire a blood disease-focused biotechnology company for as much as $2 billion, people familiar with the matter said.
Incyte Corp., the $15 billion-plus US biopharma group, is nearing a deal to buy a blood disease-focused biotechnology company for up to $2 billion, according to a person familiar with the matter, as large drugmakers continue to deploy cash reserves for pipeline acquisitions.
"This acquisition would strengthen Incyte's hematology pipeline, a therapeutic area where the company already generates billions in annual revenue from Jakafi," said Tom Brennan, M&A analyst at Edgen. "The deal size points to a late-stage asset or platform technology rather than an early-stage bet."
The transaction, reported June 7, would be one of the larger biotech acquisitions this year in a sector where deal values have averaged $800 million through the first five months of 2026, according to data from Dealogic. Incyte, with a market capitalization between $15 billion and $20 billion, has been expanding beyond its core oncology franchise into broader blood disorders, which include sickle cell disease, hemophilia, and hematologic malignancies.
The acquisition signals continued consolidation in biotech as larger pharmaceutical companies acquire pipeline assets to offset patent expirations. Incyte's Jakafi, approved for myelofibrosis and polycythemia vera, generated more than $3 billion in sales last year but faces generic competition risk later this decade. The deal is expected to close in the second half of 2026, subject to regulatory approvals. The payment structure has not been disclosed.
The takeover push comes amid a broader wave of M&A in the blood disorder space. BioCryst Pharmaceuticals Inc., a hereditary angioedema specialist with a market cap of roughly $4.5 billion, saw its shares jump 11% in after-hours trading Monday on speculation that a US biopharma company exceeding $15 billion in market value could be circling the firm. BioCryst generated $601 million in revenue last year from Orladeyo, the only oral prophylactic treatment for hereditary angioedema on the market, with patent protection extending to 2040. Chief Executive Charlie Gayer said at the TD Cowen Health Care Conference this month that the company sees its portfolio growing at mid-teens revenue rates well into the 2030s.
For Incyte, the deal would provide access to new blood disorder therapies as competition intensifies for Jakafi. The company's pipeline includes several hematology candidates in mid-to-late-stage development, and the acquisition would add depth to a franchise that generated roughly $4 billion in total product revenue last year. Advisors on both sides have not been named.
This article is for informational purposes only and does not constitute investment advice.
